Biomarkers Market Research Report - Global Forecast till 2030

Biomarkers Market Research Report: Information By Product (Consumables, Services, Software), By Type (Safety Biomarkers, Validation Biomarkers, Efficacy Biomarkers), By Application (Diagnostics, Personalized Medicine, Drug Discovery and Development, Disease Risk Assessment), By Disease Indication (Cancer, Neurological Disorders, Cardiovascular Disorders, Immunological Disorders, Others), And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) – Market Forecast Till 2030.

ID: MRFR/LS/1409-CR | 165 Pages | Published By Kinjoll Dey on April 2020         

1 EXECUTIVE SUMMARY

1.1 MARKET SYNOPSIS 16

1.2 MARKET ATTRACTIVENESS ANALYSIS 17

1.3 GLOBAL BIOMARKERS MARKET, BY PRODUCT 17

1.4 GLOBAL BIOMARKERS MARKET, BY TYPE 18

1.5 GLOBAL BIOMARKERS MARKET, BY APPLICATION 19

1.6 GLOBAL BIOMARKERS MARKET, BY DISEASE INDICATION 20

2 MARKET INTRODUCTION

2.1 DEFINITION 21

2.2 SCOPE OF THE STUDY 21

2.3 RESEARCH OBJECTIVE 21

2.4 MARKET STRUCTURE 21

2.5 ASSUMPTIONS & LIMITATIONS 22

3 RESEARCH METHODOLOGY

3.1 DATA MINING 23

3.2 SECONDARY RESEARCH 23

3.3 PRIMARY RESEARCH 25

3.4 BREAKDOWN OF PRIMARY RESPONDENTS 26

3.5 FORECASTING TECHNIQUES 26

3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION 27

3.6.1 BOTTOM-UP APPROACH 28

3.6.2 TOP-DOWN APPROACH 28

3.7 DATA TRIANGULATION 29

3.8 VALIDATION 29

4 MARKET DYNAMICS

4.1 OVERVIEW 30

4.2 DRIVERS 31

4.2.1 HIGH PREVALENCE OF CANCER 31

4.2.2 INCREASING APPLICATIONS AND ADVANCEMENTS OF BIOMARKERS 31

4.2.3 INCREASING PRODUCT LAUNCHES BY MAJOR PLAYERS 32

4.3 RESTRAINTS 33

4.3.1 HIGH CAPITAL INVESTMENT 33

4.4 OPPORTUNITIES 33

4.4.1 INCORPORATION OF ARTIFICIAL INTELLIGENCE (AI) IN THE BIOMARKER TECHNOLOGY 33

5 MARKET FACTOR ANALYSIS

5.1 PORTER’S FIVE FORCES MODEL 34

5.1.1 BARGAINING POWER OF SUPPLIERS 34

5.1.2 BARGAINING POWER OF BUYERS 35

5.1.3 THREAT OF NEW ENTRANTS 35

5.1.4 THREAT OF SUBSTITUTES 35

5.1.5 INTENSITY OF RIVALRY 35

5.2 VALUE CHAIN ANALYSIS 36

5.2.1 R&D AND DESIGNING 37

5.2.2 MANUFACTURING 37

5.2.3 DISTRIBUTION, MARKETING, AND SALES 37

5.2.4 POST-SALES MONITORING 37

6 BIOMARKERS MARKET, BY PRODUCT

6.1 OVERVIEW 38

6.2 CONSUMABLES 39

6.3 SERVICES 40

6.4 SOFTWARE 41

7 BIOMARKERS MARKET, BY TYPE

7.1 OVERVIEW 42

7.2 SAFETY BIOMARKERS 44

7.3 EFFICACY BIOMARKERS 44

7.4 VALIDATION BIOMARKERS 45

8 BIOMARKERS MARKET, BY APPLICATION

8.1 OVERVIEW 46

8.2 DIAGNOSTICS 47

8.3 PERSONALIZED MEDICINE 48

8.4 DRUG DISCOVERY AND DEVELOPMENT 49

8.5 DISEASE RISK ASSESSMENT 49

9 BIOMARKERS MARKET, BY DISEASE INDICATION

9.1 OVERVIEW 51

9.2 CANCER 53

9.3 NEUROLOGICAL DISORDERS 53

9.4 CARDIOVASCULAR DISORDERS 54

9.5 IMMUNOLOGICAL DISORDERS 55

10 GLOBAL BIOMARKERS MARKET, BY REGION

10.1 OVERVIEW 56

10.2 AMERICAS 58

BIOMARKERS MARKET, BY PRODUCT

BIOMARKERS MARKET, BY TYPE

BIOMARKERS MARKET, BY APPLICATION

BIOMARKERS MARKET, BY DISEASE INDICATION

10.2.1 NORTH AMERICA 61

BIOMARKERS MARKET, BY PRODUCT

BIOMARKERS MARKET, BY TYPE

BIOMARKERS MARKET, BY APPLICATION

BIOMARKERS MARKET, BY DISEASE INDICATION

10.2.1.1 US 64

BIOMARKERS MARKET, BY PRODUCT

BIOMARKERS MARKET, BY TYPE

BIOMARKERS MARKET, BY APPLICATION

BIOMARKERS MARKET, BY DISEASE INDICATION

10.2.1.2 CANADA 66

BIOMARKERS MARKET, BY PRODUCT

BIOMARKERS MARKET, BY TYPE

BIOMARKERS MARKET, BY APPLICATION

BIOMARKERS MARKET, BY DISEASE INDICATION

10.2.2 LATIN AMERICA 68

BIOMARKERS MARKET, BY PRODUCT

BIOMARKERS MARKET, BY TYPE

BIOMARKERS MARKET, BY APPLICATION

BIOMARKERS MARKET, BY DISEASE INDICATION

10.3 EUROPE 70

BIOMARKERS MARKET, BY PRODUCT

BIOMARKERS MARKET, BY TYPE

BIOMARKERS MARKET, BY APPLICATION

BIOMARKERS MARKET, BY DISEASE INDICATION

10.3.1 WESTERN EUROPE 73

BIOMARKERS MARKET, BY PRODUCT

BIOMARKERS MARKET, BY TYPE

BIOMARKERS MARKET, BY APPLICATION

BIOMARKERS MARKET, BY DISEASE INDICATION

10.3.1.1 GERMANY 74

BIOMARKERS MARKET, BY PRODUCT

BIOMARKERS MARKET, BY TYPE

BIOMARKERS MARKET, BY APPLICATION

BIOMARKERS MARKET, BY DISEASE INDICATION

10.3.1.2 UK 76

BIOMARKERS MARKET, BY PRODUCT

BIOMARKERS MARKET, BY TYPE

BIOMARKERS MARKET, BY APPLICATION

BIOMARKERS MARKET, BY DISEASE INDICATION

10.3.1.3 FRANCE 77

BIOMARKERS MARKET, BY PRODUCT

BIOMARKERS MARKET, BY TYPE

BIOMARKERS MARKET, BY APPLICATION

BIOMARKERS MARKET, BY DISEASE INDICATION

10.3.1.4 ITALY 79

BIOMARKERS MARKET, BY PRODUCT

BIOMARKERS MARKET, BY TYPE

BIOMARKERS MARKET, BY APPLICATION

BIOMARKERS MARKET, BY DISEASE INDICATION

10.3.1.5 SPAIN 81

BIOMARKERS MARKET, BY PRODUCT

BIOMARKERS MARKET, BY TYPE

BIOMARKERS MARKET, BY APPLICATION

BIOMARKERS MARKET, BY DISEASE INDICATION

10.3.1.6 REST OF WESTERN EUROPE 82

BIOMARKERS MARKET, BY PRODUCT

BIOMARKERS MARKET, BY TYPE

BIOMARKERS MARKET, BY APPLICATION

BIOMARKERS MARKET, BY DISEASE INDICATION

10.3.2 EASTERN EUROPE 84

BIOMARKERS MARKET, BY PRODUCT

BIOMARKERS MARKET, BY TYPE

BIOMARKERS MARKET, BY APPLICATION

BIOMARKERS MARKET, BY DISEASE INDICATION

10.4 ASIA-PACIFIC 86

BIOMARKERS MARKET, BY PRODUCT

BIOMARKERS MARKET, BY TYPE

BIOMARKERS MARKET, BY APPLICATION

BIOMARKERS MARKET, BY DISEASE INDICATION

10.4.1 CHINA 89

BIOMARKERS MARKET, BY PRODUCT

BIOMARKERS MARKET, BY TYPE

BIOMARKERS MARKET, BY APPLICATION

BIOMARKERS MARKET, BY DISEASE INDICATION

10.4.2 JAPAN 90

BIOMARKERS MARKET, BY PRODUCT

BIOMARKERS MARKET, BY TYPE

BIOMARKERS MARKET, BY APPLICATION

BIOMARKERS MARKET, BY DISEASE INDICATION

10.4.3 INDIA 92

BIOMARKERS MARKET, BY PRODUCT

BIOMARKERS MARKET, BY TYPE

BIOMARKERS MARKET, BY APPLICATION

BIOMARKERS MARKET, BY DISEASE INDICATION

10.4.4 AUSTRALIA 94

BIOMARKERS MARKET, BY PRODUCT

BIOMARKERS MARKET, BY TYPE

BIOMARKERS MARKET, BY APPLICATION

BIOMARKERS MARKET, BY DISEASE INDICATION

10.4.5 SOUTH KOREA 95

BIOMARKERS MARKET, BY PRODUCT

BIOMARKERS MARKET, BY TYPE

BIOMARKERS MARKET, BY APPLICATION

BIOMARKERS MARKET, BY DISEASE INDICATION

10.4.6 REST OF ASIA-PACIFIC 97

BIOMARKERS MARKET, BY PRODUCT

BIOMARKERS MARKET, BY TYPE

BIOMARKERS MARKET, BY APPLICATION

BIOMARKERS MARKET, BY DISEASE INDICATION

10.5 MIDDLE EAST & AFRICA 99

BIOMARKERS MARKET, BY PRODUCT

BIOMARKERS MARKET, BY TYPE

BIOMARKERS MARKET, BY APPLICATION

BIOMARKERS MARKET, BY DISEASE INDICATION

10.5.1 MIDDLE EAST 101

BIOMARKERS MARKET, BY PRODUCT

BIOMARKERS MARKET, BY TYPE

BIOMARKERS MARKET, BY APPLICATION

BIOMARKERS MARKET, BY DISEASE INDICATION

10.5.2 AFRICA 103

BIOMARKERS MARKET, BY PRODUCT

BIOMARKERS MARKET, BY TYPE

BIOMARKERS MARKET, BY APPLICATION

BIOMARKERS MARKET, BY DISEASE INDICATION

11 COMPETITIVE LANDSCAPE

11.1 OVERVIEW 105

11.2 COMPETITIVE BENCHMARKING 106

11.3 GLOBAL BIOMARKERS MARKET: COMPANY RANKING 107

11.4 LEADING PLAYERS IN TERMS OF NUMBER OF DEVELOPMENTS 108

11.5 MAJOR GROWTH STRATEGY IN THE GLOBAL BIOMARKERS MARKET 108

11.6 KEY DEVELOPMENTS & GROWTH STRATEGIES 109

11.6.1 NEW PRODUCT LAUNCHES AND APPROVALS 109

11.6.2 JOINT VENTURES 110

11.6.3 EXPANSIONS 111

11.6.4 ACQUISITIONS 111

12 COMPANY PROFILES

12.1 MESO SCALE DIAGNOSTICS, LLC 112

12.1.1 COMPANY OVERVIEW 112

12.1.2 FINANCIAL OVERVIEW 112

12.1.3 PRODUCTS/SERVICES OFFERED 112

12.1.4 KEY DEVELOPMENTS 112

12.1.5 SWOT ANALYSIS 113

12.1.6 KEY STRATEGIES 113

12.2 THERMO FISHER SCIENTIFIC INC. 114

12.2.1 COMPANY OVERVIEW 114

12.2.2 FINANCIAL OVERVIEW 114

12.2.3 PRODUCTS/SERVICES OFFERED 115

12.2.4 KEY DEVELOPMENTS 115

12.2.5 SWOT ANALYSIS 116

12.2.6 KEY STRATEGIES 116

12.3 BIO-RAD LABORATORIES, INC. 117

12.3.1 COMPANY OVERVIEW 117

12.3.2 FINANCIAL OVERVIEW 117

12.3.3 PRODUCTS/SERVICES OFFERED 118

12.3.4 KEY DEVELOPMENTS 118

12.3.5 SWOT ANALYSIS 118

12.3.6 KEY STRATEGIES 119

12.4 CISBIO 120

12.4.1 COMPANY OVERVIEW 120

12.4.2 FINANCIAL OVERVIEW 120

12.4.3 PRODUCTS/SERVICES OFFERED 121

12.4.4 KEY DEVELOPMENTS 121

12.4.5 SWOT ANALYSIS 122

12.4.6 KEY STRATEGIES 122

12.5 EKF DIAGNOSTICS 123

12.5.1 COMPANY OVERVIEW 123

12.5.2 FINANCIAL OVERVIEW 123

12.5.3 PRODUCTS/SERVICES OFFERED 124

12.5.4 KEY DEVELOPMENTS 124

12.5.5 SWOT ANALYSIS 125

12.5.6 KEY STRATEGIES 125

12.6 QIAGEN N. V. 126

12.6.1 COMPANY OVERVIEW 126

12.6.2 FINANCIAL OVERVIEW 126

12.6.3 PRODUCTS/SERVICES OFFERED 127

12.6.4 KEY DEVELOPMENTS 127

12.6.5 SWOT ANALYSIS 128

12.6.6 KEY STRATEGIES 128

12.7 ABBOTT LABORATORIES 129

12.7.1 COMPANY OVERVIEW 129

12.7.2 FINANCIAL OVERVIEW 129

12.7.3 PRODUCTS/SERVICES OFFERED 130

12.7.4 ABBOTT LABORATORIES: KEY DEVELOPMENTS 130

12.7.5 SWOT ANALYSIS 131

12.7.6 KEY STRATEGIES 131

12.8 ENZO BIOCHEM INC. 132

12.8.1 COMPANY OVERVIEW 132

12.8.2 FINANCIAL OVERVIEW 132

12.8.3 PRODUCTS/SERVICES OFFERED 133

12.8.4 KEY DEVELOPMENTS 133

12.8.5 SWOT ANALYSIS 134

12.8.6 KEY STRATEGIES 134

12.9 SIGNOSIS 135

12.9.1 COMPANY OVERVIEW 135

12.9.2 FINANCIAL OVERVIEW 135

12.9.3 PRODUCTS/SERVICES OFFERED 135

12.9.4 KEY DEVELOPMENTS 135

12.9.5 SWOT ANALYSIS 136

12.9.6 KEY STRATEGIES 136

12.10 PERKINELMER INC. 137

12.10.1 COMPANY OVERVIEW 137

12.10.2 FINANCIAL OVERVIEW 137

12.10.3 PRODUCTS/SERVICES OFFERED 138

12.10.4 KEY DEVELOPMENTS 138

12.10.5 SWOT ANALYSIS 138

12.10.6 KEY STRATEGIES 138

12.11 MERCK KGAA 139

12.11.1 COMPANY OVERVIEW 139

12.11.2 FINANCIAL OVERVIEW 139

12.11.3 PRODUCTS/SERVICES OFFERED 140

12.11.4 KEY DEVELOPMENTS 140

12.11.5 SWOT ANALYSIS 141

12.11.6 KEY STRATEGIES 141

12.12 F. HOFFMANN-LA ROCHE LTD 142

12.12.1 COMPANY OVERVIEW 142

12.12.2 FINANCIAL OVERVIEW 142

12.12.3 PRODUCTS/SERVICES OFFERED 143

12.12.4 KEY DEVELOPMENTS 143

12.12.5 SWOT ANALYSIS 144

12.12.6 KEY STRATEGIES 144

13 APPENDIX

13.1 REFERENCES 145

13.2 RELATED REPORTS 146

14 LIST OF TABLES

TABLE 1 LIST OF ASSUMPTIONS 22

TABLE 2 PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS 25

TABLE 3 GLOBAL BIOMARKERS MARKET, BY PRODUCT, 2020βˆ’2027 (USD MILLION) 39

TABLE 4 GLOBAL BIOMARKERS MARKET FOR CONSUMABLES, BY REGION, 2020βˆ’2027 (USD MILLION) 40

TABLE 5 GLOBAL BIOMARKERS MARKET FOR SERVICES, BY REGION, 2020βˆ’2027 (USD MILLION) 41

TABLE 6 GLOBAL BIOMARKERS MARKET FOR SOFTWARE, BY REGION, 2020βˆ’2027 (USD MILLION) 41

TABLE 7 GLOBAL BIOMARKERS MARKET, BY TYPE, 2020βˆ’2027 (USD MILLION) 43

TABLE 8 GLOBAL BIOMARKERS MARKET FOR EFFICACY BIOMARKERS, BY TYPE, 2020βˆ’2027 (USD MILLION) 43

TABLE 9 GLOBAL BIOMARKERS MARKET FOR SAFETY BIOMARKERS, BY REGION, 2020βˆ’2027 (USD MILLION) 44

TABLE 10 GLOBAL BIOMARKERS MARKET FOR EFFICACY BIOMARKERS, BY REGION, 2020βˆ’2027 (USD MILLION) 45

TABLE 11 GLOBAL BIOMARKERS MARKET FOR VALIDATION BIOMARKERS, BY REGION, 2020βˆ’2027 (USD MILLION) 45

TABLE 12 GLOBAL BIOMARKERS MARKET, BY APPLICATION, 2020βˆ’2027 (USD MILLION) 47

TABLE 13 GLOBAL BIOMARKERS MARKET FOR DIAGNOSTICS, BY REGION, 2020βˆ’2027 (USD MILLION) 48

TABLE 14 GLOBAL BIOMARKERS MARKET FOR PERSONALIZED MEDICINE, BY REGION, 2020βˆ’2027 (USD MILLION) 48

TABLE 15 GLOBAL BIOMARKERS MARKET FOR DRUG DISCOVERY AND DEVELOPMENT, BY REGION, 2020βˆ’2027 (USD MILLION) 49

TABLE 16 GLOBAL BIOMARKERS MARKET FOR DISEASE RISK ASSESSMENT, BY REGION, 2020βˆ’2027 (USD MILLION) 50

TABLE 17 GLOBAL BIOMARKERS MARKET, BY DISEASE INDICATION, 2020βˆ’2027 (USD MILLION) 52

TABLE 18 GLOBAL BIOMARKERS MARKET FOR CANCER, BY REGION, 2020βˆ’2027 (USD MILLION) 53

TABLE 19 GLOBAL BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS, BY REGION, 2020βˆ’2027 (USD MILLION) 54

TABLE 20 GLOBAL BIOMARKERS MARKET FOR CARDIOVASCULAR DISORDERS, BY REGION, 2020βˆ’2027 (USD MILLION) 54

TABLE 21 GLOBAL BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS, BY REGION, 2020βˆ’2027 (USD MILLION) 55

TABLE 22 GLOBAL BIOMARKERS MARKET, BY REGION, 2020βˆ’2027 (USD MILLION) 57

TABLE 23 AMERICAS: BIOMARKERS MARKET, BY REGION, 2020βˆ’2027 (USD MILLION) 59

TABLE 24 AMERICAS: BIOMARKERS MARKET, BY PRODUCT, 2020βˆ’2027 (USD MILLION) 59

TABLE 25 AMERICAS: BIOMARKERS MARKET, BY TYPE, 2020βˆ’2027 (USD MILLION) 59

TABLE 26 AMERICAS: BIOMARKERS MARKET FOR EFFICACY BIOMARKERS, BY TYPE, 2020βˆ’2027 (USD MILLION) 60

TABLE 27 AMERICAS: BIOMARKERS MARKET, BY APPLICATION, 2020βˆ’2027 (USD MILLION) 60

TABLE 28 AMERICAS: BIOMARKERS MARKET, BY DISEASE INDICATION, 2020βˆ’2027 (USD MILLION) 61

TABLE 29 NORTH AMERICA: BIOMARKERS MARKET, BY COUNTRY, 2020βˆ’2027 (USD MILLION) 61

TABLE 30 NORTH AMERICA: BIOMARKERS MARKET, BY PRODUCT, 2020βˆ’2027 (USD MILLION) 62

TABLE 31 NORTH AMERICA: BIOMARKERS MARKET, BY TYPE, 2020βˆ’2027 (USD MILLION) 62

TABLE 32 NORTH AMERICA: BIOMARKERS MARKET FOR EFFICACY BIOMARKERS, BY TYPE, 2020βˆ’2027 (USD MILLION) 62

TABLE 33 NORTH AMERICA: BIOMARKERS MARKET, BY APPLICATION, 2020βˆ’2027 (USD MILLION) 63

TABLE 34 NORTH AMERICA: BIOMARKERS MARKET, BY DISEASE INDICATION, 2020βˆ’2027 (USD MILLION) 63

TABLE 35 US: BIOMARKERS MARKET, BY PRODUCT, 2020βˆ’2027 (USD MILLION) 64

TABLE 36 US: BIOMARKERS MARKET, BY TYPE, 2020βˆ’2027 (USD MILLION) 64

TABLE 37 US: BIOMARKERS MARKET, FOR EFFICACY BIOMARKERS, BY TYPE, 2020βˆ’2027 (USD MILLION) 64

TABLE 38 US: BIOMARKERS MARKET, BY APPLICATION, 2020βˆ’2027 (USD MILLION) 65

TABLE 39 US: BIOMARKERS MARKET, BY DISEASE INDICATION, 2020βˆ’2027 (USD MILLION) 65

TABLE 40 CANADA: BIOMARKERS MARKET, BY PRODUCT, 2020βˆ’2027 (USD MILLION) 66

TABLE 41 CANADA: BIOMARKERS MARKET, BY TYPE, 2020βˆ’2027 (USD MILLION) 66

TABLE 42 CANADA: BIOMARKERS MARKET, FOR EFFICACY BIOMARKERS, BY TYPE, 2020βˆ’2027 (USD MILLION) 66

TABLE 43 CANADA: BIOMARKERS MARKET, BY APPLICATION, 2020βˆ’2027 (USD MILLION) 67

TABLE 44 CANADA: BIOMARKERS MARKET, BY DISEASE INDICATION, 2020βˆ’2027 (USD MILLION) 67

TABLE 45 LATIN AMERICA: BIOMARKERS MARKET, BY PRODUCT, 2020βˆ’2027 (USD MILLION) 68

TABLE 46 LATIN AMERICA: BIOMARKERS MARKET, BY TYPE, 2020βˆ’2027 (USD MILLION) 68

TABLE 47 LATIN AMERICA: BIOMARKERS MARKET, FOR EFFICACY BIOMARKERS, BY TYPE, 2020βˆ’2027 (USD MILLION) 68

TABLE 48 LATIN AMERICA: BIOMARKERS MARKET, BY APPLICATION, 2020βˆ’2027 (USD MILLION) 69

TABLE 49 LATIN AMERICA: BIOMARKERS MARKET, BY DISEASE INDICATION, 2020βˆ’2027 (USD MILLION) 69

TABLE 50 EUROPE: BIOMARKERS MARKET, BY REGION, 2020βˆ’2027 (USD MILLION) 71

TABLE 51 EUROPE: BIOMARKERS MARKET, BY PRODUCT, 2020βˆ’2027 (USD MILLION) 71

TABLE 52 EUROPE: BIOMARKERS MARKET, BY TYPE, 2020βˆ’2027 (USD MILLION) 71

TABLE 53 EUROPE: BIOMARKERS MARKET, FOR EFFICACY BIOMARKERS, BY TYPE, 2020βˆ’2027 (USD MILLION) 72

TABLE 54 EUROPE: BIOMARKERS MARKET, BY APPLICATION, 2020βˆ’2027 (USD MILLION) 72

TABLE 55 EUROPE: BIOMARKERS MARKET, BY DISEASE INDICATION, 2020βˆ’2027 (USD MILLION) 73

TABLE 56 WESTERN EUROPE: BIOMARKERS MARKET, BY COUNTRY, 2020βˆ’2027 (USD MILLION) 74

TABLE 57 GERMANY: BIOMARKERS MARKET, BY PRODUCT, 2020βˆ’2027 (USD MILLION) 74

TABLE 58 GERMANY: BIOMARKERS MARKET, BY TYPE, 2020βˆ’2027 (USD MILLION) 74

TABLE 59 GERMANY: BIOMARKERS MARKET, FOR EFFICACY BIOMARKERS, BY TYPE, 2020βˆ’2027 (USD MILLION) 75

TABLE 60 GERMANY: BIOMARKERS MARKET, BY APPLICATION, 2020βˆ’2027 (USD MILLION) 75

TABLE 61 GERMANY: BIOMARKERS MARKET, BY DISEASE INDICATION, 2020βˆ’2027 (USD MILLION) 75

TABLE 62 UK: BIOMARKERS MARKET, BY PRODUCT, 2020βˆ’2027 (USD MILLION) 76

TABLE 63 UK: BIOMARKERS MARKET, BY TYPE, 2020βˆ’2027 (USD MILLION) 76

TABLE 64 UK: BIOMARKERS MARKET, FOR EFFICACY BIOMARKERS, BY TYPE, 2020βˆ’2027 (USD MILLION) 76

TABLE 65 UK: BIOMARKERS MARKET, BY APPLICATION, 2020βˆ’2027 (USD MILLION) 77

TABLE 66 UK: BIOMARKERS MARKET, BY DISEASE INDICATION, 2020βˆ’2027 (USD MILLION) 77

TABLE 67 FRANCE: BIOMARKERS MARKET, BY PRODUCT, 2020βˆ’2027 (USD MILLION) 77

TABLE 68 FRANCE: BIOMARKERS MARKET, BY TYPE, 2020βˆ’2027 (USD MILLION) 78

TABLE 69 FRANCE: BIOMARKERS MARKET, FOR EFFICACY BIOMARKERS, BY TYPE, 2020βˆ’2027 (USD MILLION) 78

TABLE 70 FRANCE: BIOMARKERS MARKET, BY APPLICATION, 2020βˆ’2027 (USD MILLION) 78

TABLE 71 FRANCE: BIOMARKERS MARKET, BY DISEASE INDICATION, 2020βˆ’2027 (USD MILLION) 79

TABLE 72 ITALY: BIOMARKERS MARKET, BY PRODUCT, 2020βˆ’2027 (USD MILLION) 79

TABLE 73 ITALY: BIOMARKERS MARKET, BY TYPE, 2020βˆ’2027 (USD MILLION) 79

TABLE 74 ITALY: BIOMARKERS MARKET, FOR EFFICACY BIOMARKERS, BY TYPE, 2020βˆ’2027 (USD MILLION) 80

TABLE 75 ITALY: BIOMARKERS MARKET, BY APPLICATION, 2020βˆ’2027 (USD MILLION) 80

TABLE 76 ITALY: BIOMARKERS MARKET, BY DISEASE INDICATION, 2020βˆ’2027 (USD MILLION) 80

TABLE 77 SPAIN: BIOMARKERS MARKET, BY PRODUCT, 2020βˆ’2027 (USD MILLION) 81

TABLE 78 SPAIN: BIOMARKERS MARKET, BY TYPE, 2020βˆ’2027 (USD MILLION) 81

TABLE 79 SPAIN: BIOMARKERS MARKET, FOR EFFICACY BIOMARKERS, BY TYPE, 2020βˆ’2027 (USD MILLION) 81

TABLE 80 SPAIN: BIOMARKERS MARKET, BY APPLICATION, 2020βˆ’2027 (USD MILLION) 82

TABLE 81 SPAIN: BIOMARKERS MARKET, BY DISEASE INDICATION, 2020βˆ’2027 (USD MILLION) 82

TABLE 82 REST OF WESTERN EUROPE: BIOMARKERS MARKET, BY PRODUCT, 2020βˆ’2027 (USD MILLION) 82

TABLE 83 REST OF WESTERN EUROPE: BIOMARKERS MARKET, BY TYPE, 2020βˆ’2027 (USD MILLION) 83

TABLE 84 REST OF WESTERN EUROPE: BIOMARKERS MARKET, FOR EFFICACY BIOMARKERS, BY TYPE, 2020βˆ’2027 (USD MILLION) 83

TABLE 85 REST OF WESTERN EUROPE: BIOMARKERS MARKET, BY APPLICATION, 2020βˆ’2027 (USD MILLION) 83

TABLE 86 REST OF WESTERN EUROPE: BIOMARKERS MARKET, BY DISEASE INDICATION, 2020βˆ’2027 (USD MILLION) 84

TABLE 87 EASTERN EUROPE: BIOMARKERS MARKET, BY PRODUCT, 2020βˆ’2027 (USD MILLION) 84

TABLE 88 EASTERN EUROPE: BIOMARKERS MARKET, BY TYPE, 2020βˆ’2027 (USD MILLION) 84

TABLE 89 EASTERN EUROPE: BIOMARKERS MARKET, FOR EFFICACY BIOMARKERS, BY TYPE, 2020βˆ’2027 (USD MILLION) 85

TABLE 90 EASTERN EUROPE: BIOMARKERS MARKET, BY APPLICATION, 2020βˆ’2027 (USD MILLION) 85

TABLE 91 EASTERN EUROPE: BIOMARKERS MARKET, BY DISEASE INDICATION, 2020βˆ’2027 (USD MILLION) 85

TABLE 92 ASIA-PACIFIC: BIOMARKERS MARKET, BY COUNTRY, 2020βˆ’2027 (USD MILLION) 87

TABLE 93 ASIA-PACIFIC: BIOMARKERS MARKET, BY PRODUCT, 2020βˆ’2027 (USD MILLION) 87

TABLE 94 ASIA-PACIFIC: BIOMARKERS MARKET, BY TYPE, 2020βˆ’2027 (USD MILLION) 87

TABLE 95 ASIA-PACIFIC: BIOMARKERS MARKET, FOR EFFICACY BIOMARKERS, BY TYPE, 2020βˆ’2027 (USD MILLION) 88

TABLE 96 ASIA-PACIFIC: BIOMARKERS MARKET, BY APPLICATION, 2020βˆ’2027 (USD MILLION) 88

TABLE 97 ASIA-PACIFIC: BIOMARKERS MARKET, BY DISEASE INDICATION, 2020βˆ’2027 (USD MILLION) 88

TABLE 98 CHINA: BIOMARKERS MARKET, BY PRODUCT, 2020βˆ’2027 (USD MILLION) 89

TABLE 99 CHINA: BIOMARKERS MARKET, BY TYPE, 2020βˆ’2027 (USD MILLION) 89

TABLE 100 CHINA: BIOMARKERS MARKET, FOR EFFICACY BIOMARKERS, BY TYPE, 2020βˆ’2027 (USD MILLION) 89

TABLE 101 CHINA: BIOMARKERS MARKET, BY APPLICATION, 2020βˆ’2027 (USD MILLION) 90

TABLE 102 CHINA: BIOMARKERS MARKET, BY DISEASE INDICATION, 2020βˆ’2027 (USD MILLION) 90

TABLE 103 JAPAN: BIOMARKERS MARKET, BY PRODUCT, 2020βˆ’2027 (USD MILLION) 90

TABLE 104 JAPAN: BIOMARKERS MARKET, BY TYPE, 2020βˆ’2027 (USD MILLION) 91

TABLE 105 JAPAN: BIOMARKERS MARKET, FOR EFFICACY BIOMARKERS, BY TYPE, 2020βˆ’2027 (USD MILLION) 91

TABLE 106 JAPAN: BIOMARKERS MARKET, BY APPLICATION, 2020βˆ’2027 (USD MILLION) 91

TABLE 107 JAPAN: BIOMARKERS MARKET, BY DISEASE INDICATION, 2020βˆ’2027 (USD MILLION) 92

TABLE 108 INDIA: BIOMARKERS MARKET, BY PRODUCT, 2020βˆ’2027 (USD MILLION) 92

TABLE 109 INDIA: BIOMARKERS MARKET, BY TYPE, 2020βˆ’2027 (USD MILLION) 92

TABLE 110 INDIA: BIOMARKERS MARKET, FOR EFFICACY BIOMARKERS, BY TYPE, 2020βˆ’2027 (USD MILLION) 93

TABLE 111 INDIA: BIOMARKERS MARKET, BY APPLICATION, 2020βˆ’2027 (USD MILLION) 93

TABLE 112 INDIA: BIOMARKERS MARKET, BY DISEASE INDICATION, 2020βˆ’2027 (USD MILLION) 93

TABLE 113 AUSTRALIA: BIOMARKERS MARKET, BY PRODUCT, 2020βˆ’2027 (USD MILLION) 94

TABLE 114 AUSTRALIA: BIOMARKERS MARKET, BY TYPE, 2020βˆ’2027 (USD MILLION) 94

TABLE 115 AUSTRALIA: BIOMARKERS MARKET, FOR EFFICACY BIOMARKERS, BY TYPE, 2020βˆ’2027 (USD MILLION) 94

TABLE 116 AUSTRALIA: BIOMARKERS MARKET, BY APPLICATION, 2020βˆ’2027 (USD MILLION) 95

TABLE 117 AUSTRALIA: BIOMARKERS MARKET, BY DISEASE INDICATION, 2020βˆ’2027 (USD MILLION) 95

TABLE 118 SOUTH KOREA: BIOMARKERS MARKET, BY PRODUCT, 2020βˆ’2027 (USD MILLION) 95

TABLE 119 SOUTH KOREA: BIOMARKERS MARKET, BY TYPE, 2020βˆ’2027 (USD MILLION) 96

TABLE 120 SOUTH KOREA: BIOMARKERS MARKET, FOR EFFICACY BIOMARKERS, BY TYPE, 2020βˆ’2027 (USD MILLION) 96

TABLE 121 SOUTH KOREA: BIOMARKERS MARKET, BY APPLICATION, 2020βˆ’2027 (USD MILLION) 96

TABLE 122 SOUTH KOREA: BIOMARKERS MARKET, BY DISEASE INDICATION, 2020βˆ’2027 (USD MILLION) 97

TABLE 123 REST OF ASIA-PACIFIC: BIOMARKERS MARKET, BY PRODUCT, 2020βˆ’2027 (USD MILLION) 97

TABLE 124 REST OF ASIA-PACIFIC: BIOMARKERS MARKET, BY TYPE, 2020βˆ’2027 (USD MILLION) 97

TABLE 125 REST OF ASIA-PACIFIC: BIOMARKERS MARKET, FOR EFFICACY BIOMARKERS, BY TYPE, 2020βˆ’2027 (USD MILLION) 98

TABLE 126 REST OF ASIA-PACIFIC: BIOMARKERS MARKET, BY APPLICATION, 2020βˆ’2027 (USD MILLION) 98

TABLE 127 REST OF ASIA-PACIFIC: BIOMARKERS MARKET, BY DISEASE INDICATION, 2020βˆ’2027 (USD MILLION) 98

TABLE 128 MIDDLE EAST & AFRICA: BIOMARKERS MARKET, BY REGION, 2020βˆ’2027 (USD MILLION) 99

TABLE 129 MIDDLE EAST & AFRICA: BIOMARKERS MARKET, BY PRODUCT, 2020βˆ’2027 (USD MILLION) 100

TABLE 130 MIDDLE EAST & AFRICA: BIOMARKERS MARKET, BY TYPE, 2020βˆ’2027 (USD MILLION) 100

TABLE 131 MIDDLE EAST & AFRICA: BIOMARKERS MARKET, FOR EFFICACY BIOMARKERS, BY TYPE, 2020βˆ’2027 (USD MILLION) 100

TABLE 132 MIDDLE EAST & AFRICA: BIOMARKERS MARKET, BY APPLICATION, 2020βˆ’2027 (USD MILLION) 101

TABLE 133 MIDDLE EAST & AFRICA: BIOMARKERS MARKET, BY DISEASE INDICATION, 2020βˆ’2027 (USD MILLION) 101

TABLE 134 MIDDLE EAST: BIOMARKERS MARKET, BY PRODUCT, 2020βˆ’2027 (USD MILLION) 101

TABLE 135 MIDDLE EAST: BIOMARKERS MARKET, BY TYPE, 2020βˆ’2027 (USD MILLION) 102

TABLE 136 MIDDLE EAST: BIOMARKERS MARKET, FOR EFFICACY BIOMARKERS, BY TYPE, 2020βˆ’2027 (USD MILLION) 102

TABLE 137 MIDDLE EAST: BIOMARKERS MARKET, BY APPLICATION, 2020βˆ’2027 (USD MILLION) 102

TABLE 138 MIDDLE EAST: BIOMARKERS MARKET, BY DISEASE INDICATION, 2020βˆ’2027 (USD MILLION) 103

TABLE 139 AFRICA: BIOMARKERS MARKET, BY PRODUCT, 2020βˆ’2027 (USD MILLION) 103

TABLE 140 AFRICA: BIOMARKERS MARKET, BY TYPE, 2020βˆ’2027 (USD MILLION) 103

TABLE 141 AFRICA: BIOMARKERS MARKET, FOR EFFICACY BIOMARKERS, BY TYPE, 2020βˆ’2027 (USD MILLION) 104

TABLE 142 AFRICA: BIOMARKERS MARKET, BY APPLICATION, 2020βˆ’2027 (USD MILLION) 104

TABLE 143 AFRICA: BIOMARKERS MARKET, BY DISEASE INDICATION, 2020βˆ’2027 (USD MILLION) 104

TABLE 144 MAJOR MANUFACTURERS RANKING, 2020 107

TABLE 145 TOP PLAYERS IN TERMS OF NUMBER OF DEVELOPMENTS IN THE BIOMARKERS MARKET 108

TABLE 146 NEW PRODUCT LAUNCHES AND APPROVALS 109

TABLE 147 JOINT VENTURES 110

TABLE 148 EXPANSIONS 111

TABLE 149 ACQUISITIONS 111

TABLE 150 MESO SCALE DIAGNOSTICS, LLC: PRODUCTS/SERVICES OFFERED 112

TABLE 151 MESO SCALE DIAGNOSTICS, LLC: KEY DEVELOPMENTS 112

TABLE 152 THERMO FISHER SCIENTIFIC INC.: PRODUCTS/SERVICES OFFERED 115

TABLE 153 THERMO FISHER SCIENTIFIC INC.: KEY DEVELOPMENTS 115

TABLE 154 BIO-RAD LABORATORIES, INC.: PRODUCTS/SERVICES OFFERED 118

TABLE 155 BIO-RAD LABORATORIES, INC.: KEY DEVELOPMENTS 118

TABLE 156 CISBIO: PRODUCTS/SERVICES OFFERED 121

TABLE 157 EKF DIAGNOSTICS: PRODUCTS/SERVICES OFFERED 124

TABLE 158 EKF DIAGNOSTICS: KEY DEVELOPMENTS 124

TABLE 159 QIAGEN: PRODUCTS/SERVICES OFFERED 127

TABLE 160 QIAGEN: KEY DEVELOPMENTS 127

TABLE 161 ABBOTT LABORATORIES: PRODUCTS/SERVICES OFFERED 130

TABLE 162 KEY DEVELOPMENTS 130

TABLE 163 ENZO BIOCHEM INC.: PRODUCTS/SERVICES OFFERED 133

TABLE 164 ENZO BIOCHEM INC.: KEY DEVELOPMENTS 133

TABLE 165 SIGNOSIS: PRODUCTS/SERVICES OFFERED 135

TABLE 166 PERKINELMER INC.: PRODUCTS/SERVICES OFFERED 138

TABLE 167 MERCK KGAA: PRODUCTS/SERVICES OFFERED 140

TABLE 168 MERCK KGAA: KEY DEVELOPMENTS 140

TABLE 169 F. HOFFMANN-LA ROCHE LTD: PRODUCTS/SERVICES OFFERED 143

TABLE 170 F. HOFFMANN-LA ROCHE LTD: KEY DEVELOPMENTS 143

15 LIST OF FIGURES

FIGURE 1 MARKET SYNOPSIS 16

FIGURE 2 MARKET ATTRACTIVENESS ANALYSIS (2020) 17

FIGURE 3 GLOBAL BIOMARKERS MARKET, BY PRODUCT 17

FIGURE 4 GLOBAL BIOMARKERS MARKET, BY TYPE 18

FIGURE 5 GLOBAL BIOMARKERS MARKET, BY APPLICATION 19

FIGURE 6 GLOBAL BIOMARKERS MARKET, BY DISEASE INDICATION 20

FIGURE 7 GLOBAL BIOMARKERS MARKET STRUCTURE 21

FIGURE 8 BOTTOM-UP AND TOP-DOWN APPROACHES 28

FIGURE 9 MARKET DYNAMICS ANALYSIS: GLOBAL BIOMARKERS MARKET 30

FIGURE 10 DRIVERS: IMPACT ANALYSIS 32

FIGURE 11 RESTRAINTS: IMPACT ANALYSIS 33

FIGURE 12 PORTER’S FIVE FORCES ANALYSIS: GLOBAL BIOMARKERS MARKET 34

FIGURE 13 VALUE CHAIN ANALYSIS OF THE GLOBAL BIOMARKERS MARKET 36

FIGURE 14 GLOBAL BIOMARKERS MARKET, BY PRODUCT, 2020 (%) 38

FIGURE 15 GLOBAL BIOMARKERS MARKET, BY PRODUCT, 2020 & 2027 (USD MILLION) 39

FIGURE 16 GLOBAL BIOMARKERS MARKET, BY TYPE, 2020 (%) 42

FIGURE 17 GLOBAL BIOMARKERS MARKET, BY TYPE, 2020 & 2027 (USD MILLION) 43

FIGURE 18 GLOBAL BIOMARKERS MARKET, BY APPLICATION, 2020 (%) 46

FIGURE 19 GLOBAL BIOMARKERS MARKET, BY APPLICATION, 2020 & 2027 (USD MILLION) 47

FIGURE 20 GLOBAL BIOMARKERS MARKET, BY DISEASE INDICATION, 2020 (%) 51

FIGURE 21 GLOBAL BIOMARKERS MARKET, BY DISEASE INDICATION, 2020 & 2027 (USD MILLION) 52

FIGURE 22 GLOBAL BIOMARKERS MARKET, BY REGION, 2020 (%) 56

FIGURE 23 GLOBAL BIOMARKERS MARKET, BY REGION, 2020 & 2027 (USD MILLION) 56

FIGURE 24 AMERICAS: BIOMARKERS MARKET, BY REGION, 2020 (%) 58

FIGURE 25 NORTH AMERICA: BIOMARKERS MARKET, BY COUNTRY, 2020 (%) 61

FIGURE 26 EUROPE: BIOMARKERS MARKET, BY REGION, 2020 (%) 70

FIGURE 27 WESTERN EUROPE: BIOMARKERS MARKET, BY COUNTRY, 2020 (%) 73

FIGURE 28 ASIA-PACIFIC: BIOMARKERS MARKET, BY COUNTRY, 2020 (%) 86

FIGURE 29 MIDDLE EAST & AFRICA: BIOMARKERS MARKET, BY REGION, 2020 (%) 99

FIGURE 30 BENCHMARKING OF MAJOR COMPETITORS 106

FIGURE 31 MAJOR STRATEGY ADOPTED BY KEY PLAYERS IN THE GLOBAL BIOMARKERS MARKET 108

FIGURE 32 MESO SCALE DIAGNOSTICS, LLC: SWOT ANALYSIS 113

FIGURE 33 THERMO FISHER SCIENTIFIC INC.: FINANCIAL OVERVIEW SNAPSHOT 114

FIGURE 34 THERMO FISHER SCIENTIFIC INC.: SWOT ANALYSIS 116

FIGURE 35 BIO-RAD LABORATORIES, INC.: FINANCIAL OVERVIEW SNAPSHOT 117

FIGURE 36 BIO-RAD LABORATORIES, INC: SWOT ANALYSIS 118

FIGURE 37 CISBIO: FINANCIAL OVERVIEW SNAPSHOT 120

FIGURE 38 CISBIO: SWOT ANALYSIS 122

FIGURE 39 EKF DIAGNOSTICS: FINANCIAL OVERVIEW SNAPSHOT 123

FIGURE 40 EKF DIAGNOSTICS: SWOT ANALYSIS 125

FIGURE 41 QIAGEN: FINANCIAL OVERVIEW SNAPSHOT 126

FIGURE 42 QIAGEN: SWOT ANALYSIS 128

FIGURE 43 ABBOTT LABORATORIES: FINANCIAL OVERVIEW SNAPSHOT 129

FIGURE 44 ABBOTT LABORATORIES: SWOT ANALYSIS 131

FIGURE 45 ENZO BIOCHEM INC.: FINANCIAL OVERVIEW SNAPSHOT 132

FIGURE 46 ENZO BIOCHEM INC.: SWOT ANALYSIS 134

FIGURE 47 SIGNOSIS: SWOT ANALYSIS 136

FIGURE 48 PERKINELMER INC.: FINANCIAL OVERVIEW SNAPSHOT 137

FIGURE 49 PERKINELMER INC.: SWOT ANALYSIS 138

FIGURE 50 MERCK KGAA: FINANCIAL OVERVIEW SNAPSHOT 139

FIGURE 51 MERCK KGAA: SWOT ANALYSIS 141

FIGURE 52 F. HOFFMANN-LA ROCHE LTD: FINANCIAL OVERVIEW SNAPSHOT 142

FIGURE 53 F. HOFFMANN-LA ROCHE LTD: SWOT ANALYSIS 144

Β 


Market Segmentation


Biomarkers Product Outlook (USD Billion, 2019-2030)




  • Consumables




  • Services




  • Software




Biomarkers Type Outlook (USD Billion, 2019-2030)




  • Safety Biomarkers




  • Validation Biomarkers




  • Efficacy Biomarkers




Biomarkers Application Outlook (USD Billion, 2019-2030)




  • Diagnostics




  • Personalized Medicine




  • Drug Discovery and Development




  • Disease Risk Assessment




Biomarkers Disease Indication Outlook (USD Billion, 2019-2030)




  • Cancer




  • Neurological Disorders




  • Cardiovascular Disorders




  • Immunological Disorders




  • Others




Biomarkers Regional Outlook (USD Billion, 2019-2030)




  • North America Outlook (USD Billion, 2019-2030)




    • North America Biomarkers by Product




      • Consumables




      • Services




      • Software






    • North America Biomarkers by Type




      • Safety Biomarkers




      • Validation Biomarkers




      • Efficacy Biomarkers






    • North America Biomarkers by Application




      • Diagnostics




      • Personalized Medicine




      • Drug Discovery and Development




      • Disease Risk Assessment






    • North America Biomarkers by Disease Indication




      • Cancer




      • Neurological Disorders




      • Cardiovascular Disorders




      • Immunological Disorders




      • Others






    • US Outlook (USD Billion, 2019-2030)




    • US Biomarkers by Product




      • Consumables




      • Services




      • Software






    • US Biomarkers by Type




      • Safety Biomarkers




      • Validation Biomarkers




      • Efficacy Biomarkers






    • US Biomarkers by Application




      • Diagnostics




      • Personalized Medicine




      • Drug Discovery and Development




      • Disease Risk Assessment






    • US Biomarkers by Disease Indication




      • Cancer




      • Neurological Disorders




      • Cardiovascular Disorders




      • Immunological Disorders




      • Others






    • CANADA Outlook (USD Billion, 2019-2030)




    • CANADA Biomarkers by Product




      • Consumables




      • Services




      • Software






    • CANADA Biomarkers by Type




      • Safety Biomarkers




      • Validation Biomarkers




      • Efficacy Biomarkers






    • CANADA Biomarkers by Application




      • Diagnostics




      • Personalized Medicine




      • Drug Discovery and Development




      • Disease Risk Assessment






    • CANADA Biomarkers by Disease Indication




      • Cancer




      • Neurological Disorders




      • Cardiovascular Disorders




      • Immunological Disorders




      • Others








  • Europe Outlook (USD Billion, 2019-2030)




    • Europe Biomarkers by Product




      • Consumables




      • Services




      • Software






    • Europe Biomarkers by Type




      • Safety Biomarkers




      • Validation Biomarkers




      • Efficacy Biomarkers






    • Europe Biomarkers by Application




      • Diagnostics




      • Personalized Medicine




      • Drug Discovery and Development




      • Disease Risk Assessment






    • Europe Biomarkers by Disease Indication




      • Cancer




      • Neurological Disorders




      • Cardiovascular Disorders




      • Immunological Disorders




      • Others






    • Germany Outlook (USD Billion, 2019-2030)




    • Germany Biomarkers by Product




      • Consumables




      • Services




      • Software






    • Germany Biomarkers by Type




      • Safety Biomarkers




      • Validation Biomarkers




      • Efficacy Biomarkers






    • Germany Biomarkers by Application




      • Diagnostics




      • Personalized Medicine




      • Drug Discovery and Development




      • Disease Risk Assessment






    • Germany Biomarkers by Disease Indication




      • Cancer




      • Neurological Disorders




      • Cardiovascular Disorders




      • Immunological Disorders




      • Others






    • France Outlook (USD Billion, 2019-2030)




    • France Biomarkers by Product




      • Consumables




      • Services




      • Software






    • France Biomarkers by Type




      • Safety Biomarkers




      • Validation Biomarkers




      • Efficacy Biomarkers






    • France Biomarkers by Application




      • Diagnostics




      • Personalized Medicine




      • Drug Discovery and Development




      • Disease Risk Assessment






    • France Biomarkers by Disease Indication




      • Cancer




      • Neurological Disorders




      • Cardiovascular Disorders




      • Immunological Disorders




      • Others






    • UK Outlook (USD Billion, 2019-2030)




    • UK Biomarkers by Product




      • Consumables




      • Services




      • Software






    • UK Biomarkers by Type




      • Safety Biomarkers




      • Validation Biomarkers




      • Efficacy Biomarkers






    • UK Biomarkers by Application




      • Diagnostics




      • Personalized Medicine




      • Drug Discovery and Development




      • Disease Risk Assessment






    • UK Biomarkers by Disease Indication




      • Cancer




      • Neurological Disorders




      • Cardiovascular Disorders




      • Immunological Disorders




      • Others






    • ITALY Outlook (USD Billion, 2019-2030)




    • ITALY Biomarkers by Product




      • Consumables




      • Services




      • Software






    • ITALY Biomarkers by Type




      • Safety Biomarkers




      • Validation Biomarkers




      • Efficacy Biomarkers






    • ITALY Biomarkers by Application




      • Diagnostics




      • Personalized Medicine




      • Drug Discovery and Development




      • Disease Risk Assessment






    • ITALY Biomarkers by Disease Indication




      • Cancer




      • Neurological Disorders




      • Cardiovascular Disorders




      • Immunological Disorders




      • Others














    • SPAIN Outlook (USD Billion, 2019-2030)




    • SPAIN Biomarkers by Product




      • Consumables




      • Services




      • Software






    • SPAIN Biomarkers by Type




      • Safety Biomarkers




      • Validation Biomarkers




      • Efficacy Biomarkers






    • SPAIN Biomarkers by Application




      • Diagnostics




      • Personalized Medicine




      • Drug Discovery and Development




      • Disease Risk Assessment






    • SPAIN Biomarkers by Disease Indication




      • Cancer




      • Neurological Disorders




      • Cardiovascular Disorders




      • Immunological Disorders




      • Others






    • Rest Of Europe Outlook (USD Billion, 2019-2030)




    • Rest Of Europe Biomarkers by Product




      • Consumables




      • Services




      • Software






    • Rest Of Europe Biomarkers by Type




      • Safety Biomarkers




      • Validation Biomarkers




      • Efficacy Biomarkers






    • Rest Of Europe Biomarkers by Application




      • Diagnostics




      • Personalized Medicine




      • Drug Discovery and Development




      • Disease Risk Assessment






    • Rest Of Europe Biomarkers by Disease Indication




      • Cancer




      • Neurological Disorders




      • Cardiovascular Disorders




      • Immunological Disorders




      • Others







  • Asia-Pacific Outlook (USD Billion, 2019-2030)




    • Asia-Pacific Biomarkers by Product




      • Consumables




      • Services




      • Software






    • Asia-Pacific Biomarkers by Type




      • Safety Biomarkers




      • Validation Biomarkers




      • Efficacy Biomarkers






    • Asia-Pacific Biomarkers by Application




      • Diagnostics




      • Personalized Medicine




      • Drug Discovery and Development




      • Disease Risk Assessment






    • Asia-Pacific Biomarkers by Disease Indication




      • Cancer




      • Neurological Disorders




      • Cardiovascular Disorders




      • Immunological Disorders




      • Others






    • China Outlook (USD Billion, 2019-2030)




    • China Biomarkers by Product




      • Consumables




      • Services




      • Software






    • China Biomarkers by Type




      • Safety Biomarkers




      • Validation Biomarkers




      • Efficacy Biomarkers






    • China Biomarkers by Application




      • Diagnostics




      • Personalized Medicine




      • Drug Discovery and Development




      • Disease Risk Assessment






    • China Biomarkers by Disease Indication




      • Cancer




      • Neurological Disorders




      • Cardiovascular Disorders




      • Immunological Disorders




      • Others






    • Japan Outlook (USD Billion, 2019-2030)




    • Japan Biomarkers by Product




      • Consumables




      • Services




      • Software






    • Japan Biomarkers by Type




      • Safety Biomarkers




      • Validation Biomarkers




      • Efficacy Biomarkers






    • Japan Biomarkers by Application




      • Diagnostics




      • Personalized Medicine




      • Drug Discovery and Development




      • Disease Risk Assessment






    • Japan Biomarkers by Disease Indication




      • Cancer




      • Neurological Disorders




      • Cardiovascular Disorders




      • Immunological Disorders




      • Others






    • India Outlook (USD Billion, 2019-2030)




    • India Biomarkers by Product




      • Consumables




      • Services




      • Software






    • India Biomarkers by Type




      • Safety Biomarkers




      • Validation Biomarkers




      • Efficacy Biomarkers






    • India Biomarkers by Application




      • Diagnostics




      • Personalized Medicine




      • Drug Discovery and Development




      • Disease Risk Assessment






    • India Biomarkers by Disease Indication




      • Cancer




      • Neurological Disorders




      • Cardiovascular Disorders




      • Immunological Disorders




      • Others






    • Australia Outlook (USD Billion, 2019-2030)




    • Australia Biomarkers by Product




      • Consumables




      • Services




      • Software






    • Australia Biomarkers by Type




      • Safety Biomarkers




      • Validation Biomarkers




      • Efficacy Biomarkers






    • Australia Biomarkers by Application




      • Diagnostics




      • Personalized Medicine




      • Drug Discovery and Development




      • Disease Risk Assessment






    • Australia Biomarkers by Disease Indication




      • Cancer




      • Neurological Disorders




      • Cardiovascular Disorders




      • Immunological Disorders




      • Others






    • Rest of Asia-Pacific Outlook (USD Billion, 2019-2030)




    • Rest of Asia-Pacific Biomarkers by Product




      • Consumables




      • Services




      • Software






    • Rest of Asia-Pacific Biomarkers by Type




      • Safety Biomarkers




      • Validation Biomarkers




      • Efficacy Biomarkers






    • Rest of Asia-Pacific Biomarkers by Application




      • Diagnostics




      • Personalized Medicine




      • Drug Discovery and Development




      • Disease Risk Assessment






    • Rest of Asia-Pacific Biomarkers by Disease Indication




      • Cancer




      • Neurological Disorders




      • Cardiovascular Disorders




      • Immunological Disorders




      • Others








  • Rest of the World Outlook (USD Billion, 2019-2030)




    • Rest of the World Biomarkers by Product




      • Consumables




      • Services




      • Software






    • Rest of the World Biomarkers by Type




      • Safety Biomarkers




      • Validation Biomarkers




      • Efficacy Biomarkers






    • Rest of the World Biomarkers by Application




      • Diagnostics




      • Personalized Medicine




      • Drug Discovery and Development




      • Disease Risk Assessment






    • Rest of the World Biomarkers by Disease Indication




      • Cancer




      • Neurological Disorders




      • Cardiovascular Disorders




      • Immunological Disorders




      • Others






    • Middle East Outlook (USD Billion, 2019-2030)




    • Middle East Biomarkers by Product




      • Consumables




      • Services




      • Software






    • Middle East Biomarkers by Type




      • Safety Biomarkers




      • Validation Biomarkers




      • Efficacy Biomarkers






    • Middle East Biomarkers by Application




      • Diagnostics




      • Personalized Medicine




      • Drug Discovery and Development




      • Disease Risk Assessment






    • Middle East Biomarkers by Disease Indication




      • Cancer




      • Neurological Disorders




      • Cardiovascular Disorders




      • Immunological Disorders




      • Others






    • Africa Outlook (USD Billion, 2019-2030)




    • Africa Biomarkers by Product




      • Consumables




      • Services




      • Software






    • Africa Biomarkers by Type




      • Safety Biomarkers




      • Validation Biomarkers




      • Efficacy Biomarkers






    • Africa Biomarkers by Application




      • Diagnostics




      • Personalized Medicine




      • Drug Discovery and Development




      • Disease Risk Assessment






    • Africa Biomarkers by Disease Indication




      • Cancer




      • Neurological Disorders




      • Cardiovascular Disorders




      • Immunological Disorders




      • Others






    • Latin America Outlook (USD Billion, 2019-2030)




    • Latin America Biomarkers by Product




      • Consumables




      • Services




      • Software






    • Latin America Biomarkers by Type




      • Safety Biomarkers




      • Validation Biomarkers




      • Efficacy Biomarkers






    • Latin America Biomarkers by Application




      • Diagnostics




      • Personalized Medicine




      • Drug Discovery and Development




      • Disease Risk Assessment






    • Latin America Biomarkers by Disease Indication




      • Cancer




      • Neurological Disorders




      • Cardiovascular Disorders




      • Immunological Disorders




      • Others